Complementary, alternative and traditional medicines — branching viva

Opening (warm-up)

Examiner: "You are the general paediatric registrar. I am handing you two children. In the first, a four-year-old of South Asian heritage presents with abdominal pain, constipation and a microcytic anaemia; the mother mentions an Ayurvedic preparation the child has been taking for strength. In the second, the mother of a 10-year-old with epilepsy has started giving him St John's wort for his mood. Tell me how you think about each." [1]

Model answer: Both are complementary and alternative medicine (CAM) exposures, but they carry different risks through the same four-pathway framework. The Ayurvedic preparation is a whole medical system product and the principal concern is heavy-metal contamination — the child's abdominal pain, constipation and anaemia make lead poisoning the leading diagnosis, so I would send a venous blood lead level. The St John's wort is a biologically based therapy (a botanical) and the principal concern is a herb-drug interaction — St John's wort induces CYP3A4 and P-glycoprotein and can lower antiseizure medicine levels, so I would ask exactly which antiseizure drugs he takes, check the levels, and advise stopping the St John's wort. [8] [5]

Branch 1 — probe the classification

Examiner: "Give me the five CAM domains." [1]

Model answer: The five NCCIH domains are: (1) biologically based therapies — herbs, botanicals, vitamins, minerals, probiotics, dietary supplements; (2) mind-body medicine — meditation, relaxation, hypnosis, yoga, biofeedback; (3) manipulative and body-based practices — massage, chiropractic, osteopathy; (4) energy therapies — Reiki, therapeutic touch, electromagnetic-field therapies; (5) whole medical systems — Ayurveda, traditional Chinese medicine, homeopathy, naturopathy, and Indigenous healing traditions. The biologically based and whole-systems domains carry the most paediatric risk. [1]

Examiner (corner): "Is homeopathy the same as herbal medicine?" [10]

Model answer: No. Herbal medicine uses biologically active plant material at pharmacological doses; homeopathy is based on the doctrines of similia (like cures like) and extreme dilution, such that most homeopathic products contain little or no active ingredient. The 2022 Cochrane review found no evidence that homeopathic products prevent or treat acute respiratory tract infections in children, and homeopathy must not replace proven treatment. [10]

Branch 2 — prevalence and the disclosure gap

Examiner: "How common is CAM use in children, and why does it matter that you ask?" [1]

Model answer: CAM use is common — Ernst's 1999 systematic review established the scale, and subsequent surveys including Frawley's 2017 Australian study and Stampini's 2019 Italian study confirm a meaningful minority to a majority of children are exposed. Prevalence peaks in chronic illness — Bishop's 2010 systematic review in paediatric cancer and Zhu's 2022 review in childhood epilepsy. The reason asking matters is that non-disclosure is the default: most families do not tell their doctor unless asked directly and without judgement, so the four hidden pathways stay hidden until someone asks. [1] [4]

Branch 3 — the four pathways (the core)

Examiner: "Walk me through the four ways CAM harms a child." [7]

Model answer — four pathways, each with a mechanism and an example: [7]

1. Adulteration and heavy-metal contamination — Ayurvedic bhasmas, traditional Chinese medicines and imported remedies may contain lead, arsenic or mercury; the four-year-old in front of me is the example, and the reference is McRae's 2024 systematic review and Datta-Mitra's 2015 case. [6] [8]
2. Herb-drug interactions via CYP3A4 and P-glycoprotein — St John's wort is the archetype, lowering ciclosporin, tacrolimus, warfarin, oral contraceptives, anticonvulsants and HIV protease inhibitors; the 10-year-old with epilepsy is the example. [5]
3. Misidentification and dosing inconsistency — star-anise tea contaminated with the neurotoxic Japanese star anise causes seizures in infants given the tea for colic; batch-to-batch variation makes the dose unknowable. [5]
4. Delay or displacement of conventional care — substituting an unproven CAM product for proven treatment is the most serious harm and a safeguarding as well as a pharmacology problem. [4]

Examiner (corner): "What about the perioperative question?" [5]

Model answer: Coagulation-affecting herbs — ginkgo, garlic, ginseng, ginger, high-dose fish oil — and sedation-affecting herbs — valerian, kava — need to be identified and stopped before surgery, which is why the pre-operative CAM history is a patient-safety question. [5]

Branch 4 — the bedside safety conversation

Examiner: "What do you actually say to the family of the four-year-old?" [4]

Model answer — six steps: [4]

1. Ask respectfully and routinely — I use open, normalised wording so the parent does not feel judged. [4]
2. Document every remedy — name, dose, frequency, route, source and recommender, in the chart. [4]
3. Screen for interactions and contamination — here, the Ayurvedic preparation flags heavy-metal contamination. [7]
4. Assess the evidence and the risk — is it harmful, is it substituting for care, is the child vulnerable? [4]
5. Counsel honestly and collaboratively — I explain my concern in plain language, respect the family's cultural framework, and use shared decision-making; I do not dismiss their beliefs. [4]
6. Coordinate and follow up — I arrange the blood lead level, stop the product pending the result, involve toxicology, and report the event if confirmed. [8]

Branch 5 — the regulatory picture

Examiner: "Does regulation protect children here?" [10]

Model answer: Partially. The WHO Traditional Medicine Strategy frames safe integration. In the UK, the MHRA's Traditional Herbal Registration covers quality and safety for registered products, but unregistered and compounded remedies are where contamination enters. In Australia, the TGA's listed medicines (AUST L) meet quality and safety but not efficacy standards — which is why a product can be legally sold yet lack evidence. In the US, DSHEA 1994 treats supplements like foods, so manufacturers do not have to prove safety or efficacy before marketing, and the burden falls on the FDA to show harm. Across all regions the regulation of CAM is lighter than for conventional medicines, so the clinician's bedside question — not the regulatory label — is the child's main safety net. [7] [8]

Closing probe

Examiner: "Give me one sentence a parent would understand." [4]

Model answer: "Lots of families give their children herbs or traditional remedies alongside prescribed medicines, and most are harmless — but some can interact with your child's treatment or contain harmful metals, so it really helps if you tell me about everything your child takes, and we can decide together what is safe to continue." [4]